Please login to the form below

Not currently logged in
Email:
Password:

anti-PD1

This page shows the latest anti-PD1 news and features for those working in and with pharma, biotech and healthcare.

MSD’s Keytruda wins bladder cancer indication in Japan

MSD’s Keytruda wins bladder cancer indication in Japan

MSD’ s Keytruda wins bladder cancer indication in Japan. Becomes first anti-PD1 approved in the country for previously treated UC. ... The approval marks additional positive news for MSD, as it makes Keytruda the first anti-PD1 therapy approved in the

Latest news

More from news
Approximately 17 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13) in skin diseases. ... Licence. 1, 115. Sorrento Therapeutics/ Servier. STI-A1110 - anti-PD1 immune checkpoint mAb.

  • Deal Watch April 2016 Deal Watch April 2016

    Under this agreement Pieris pay $0.25m to obtain a license to Enumeral's 388D4 anti-PD1 antibody programme. ... 125 . Enumeral (US). Pieris (DE). License &option to further programme. Discovery state 388D4 programme of PD1 Monoclonal Antibodies

  • Pharma deals during August 2013 Pharma deals during August 2013

    These programmes involve “ anti programmed cell death monoclonal antibodies” (PD-1 mABs), which suppress tumour-initiated defence mechanisms and allow the immune system to recognise and destroy cancer cells. ... The $500m acquisition of Amplimmune

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Merck’s Richard Murray joins Jounce as CEO Merck’s Richard Murray joins Jounce as CEO

    During his time at Merck he led the advancement of protein therapeutics and vaccines across a range of therapy areas, including Merck's immunotherapy programme for its promising anti-PD1 drug

  • Merck Serono names R&D head Merck Serono names R&D head

    In this role he was influential in shaping the development strategy of Merck &Co's promising anti-PD1 therapy pembrolizumab.

  • Bruno Strigini leaves Merck & Co for Novartis Bruno Strigini leaves Merck & Co for Novartis

    CoStim and its pipeline of oncology candidates, including an ant-PD1 drug. ... The area of anti-PD1 cancer immunotherapies looks to be an important one for many companies, with Bristol-Myers Squibb, Roche and AstraZeneca all developing their own products.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics